• The annual awards created by the Zendal group aim to promote and encourage new research projects in the field of health.
  • The deadline for submitting applications will be open until September 19th.
  • Open to both public and private institutions, these awards are endowed with 40,000 euros for the human health category and 25,000 euros for the animal health category.

O Porriño, June 4, 2025 – The International Zendal Awards, organized by the Zendal Group, are now in their sixth edition. These annual awards, established by the biopharmaceutical group in 2019, aim to promote, raise awareness of, and recognize new research projects in the field of human and animal health.

Year after year, the number of applications and projects has gradually increased, exceeding one hundred applications in the last edition, which is a testament to the scientific quality of many research groups both nationally and internationally.

These awards are open to institutions and teams, both public and private. There are two categories: human health, with a prize of €40,000, and animal health, with €25,000.

For the awarding of the prizes, special consideration will be given to applications that have made significant contributions to research, biotechnology, and health with innovative and transformative solutions. Furthermore, to ensure the most objective selection possible, factors such as the project’s feasibility, applicability, and contribution to improving life in terms of progress and well-being will be taken into account.

Applications can be submitted until September 19th through the Zendal website. www.zendal.com

A lifetime achievement award is also given to recognize a distinguished career. This award is given to individuals who have contributed their work and merits in the scientific field to the development of vaccines and other health products, prevention, biotechnology, and the One Health concept.

Among the award winners in previous editions are Marisol Soengas, who leads the melanoma group at the CNIO, Dr. Ángel Carracedo, director of the Galician Public Foundation for Genomic Medicine (SERGAS-Xunta de Galicia), María Vallet Regí, head of the CIBER-BBN group at the Complutense University of Madrid, and Inmaculada Ibáñez de Cáceres, PhD in Molecular Biology.

The jury will consist of an International Scientific Committee made up of prominent figures in the field of biotechnology and health, as well as a president and a secretary from the Zendal Group.

About Zendal Group

Zendal is the corporate brand of the biotechnology group focused on the research, development, manufacturing, and marketing of human and animal vaccines and other high-value-added pharmaceutical products for the healthcare sector. It has three R&D centers and several biopharmaceutical production plants in its laboratories in O Porriño, León, Barcelona, ​​and Paredes de Coura (Portugal).